INDERAL 40mg Price

Overview

Welcome to Dwaey, specifically on INDERAL 40mg Tablets/Film-coated page.
This medicine contains an important and useful components, as it consists of Propranolol HCl.
INDERAL 40mg is available in the market in concentration 40mg/Tablet and in the form of Tablets/Film-coated.

ASTRAZENECA UK LIMITED is the producer of INDERAL 40mg and it is imported from UK, The most popular alternatives of INDERAL 40mg are listed downward .

Mode Of Action

Propranolol is a non-cardioselective beta-blocker that competitively blocks beta1- and beta2-receptors resulting in decreased heart rate, myocardial contractility, BP and myocardial oxygen demand. It has membrane-stabilising properties.

Indication

• Tuberculosis
• Hypertrophic cardiomyopathy
• MI
• Anxiety
• Diabetic nephropathy
• HTN
• Cardiac arrhythmias
• Angina pectoris
• Phaeochromocytoma
• Migraine prophylaxis
• Essential tremor

Precaution

Sinus node dysfunction, DM, history of nonallergic bronchospasm (e.g. chronic bronchitis, emphysema), myasthenia gravis, 1st degree heart block. May mask signs of hyperthyroidism and hypoglycaemia. Renal or hepatic impairment. Abrupt withdrawal may exacerbate angina symptoms or precipitate MI in patients w/ coronary artery disease. Elderly. Pregnancy and lactation. Patient Counselling Avoid cigarette smoking. Monitoring Parameters Monitor ECG, heart rate and BP.

Side Effects

• Most adverse effects have been mild and transient and have rarely required the withdrawal of therapy. Cardiovascular: Bradycardia; congestive heart failure; intensification of AV block; hypotension; paresthesia of hands; thrombocytopenic purpura; arterial insufficiency
• usually of the Raynaud type. Central Nervous System: Lightheadedness; mental depression manifested by insomnia
• lassitude
• weakness
• fatigue; reversible mental depression progressing to catatonia; visual disturbances; hallucinations; vivid dreams; an acute reversible syndrome characterized by disorientation for time and place
• short-term memory loss
• emotional lability
• slightly clouded sensorium
• and decreased performance on neuropsychometrics. For immediate formulations
• fatigue
• lethargy
• and vivid dreams appear dose related. Gastrointestinal: Nausea
• vomiting
• epigastric distress
• abdominal cramping
• diarrhea
• constipation
• mesenteric arterial thrombosis
• and ischemic colitis. Allergic: Hypersensitivity reactions
• including anaphylactic/anaphylactoid reactions
• pharyngitis and agranulocytosis
• erythematous rash
• fever combined with aching and sore throat
• laryngospasm
• and respiratory distress. Respiratory: Bronchospasm. Hematologic: Agranulocytosis
• nonthrombocytopenic purpura
• and thrombocytopenic purpura. Skin: Stevens-Johnson Syndrome
• toxic epidermal necrolysis
• exfoliative dermatitis
• erythema multiforme
• and urticaria.

Contra indication

Sinus bradycardia, cardiogenic shock, sick sinus syndrome, Raynaud's syndrome, 2nd and 3rd degree heart block, overt CHF, bronchial asthma, COPD, untreated phaeochromocytoma, Prinzmetal's angina; severe peripheral arterial disease, metabolic acidosis. Concomitant use w/ thioridazine.

Pregnancy and lactation

Pregnancy category: C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks

Pregnancy category: C, D in 2nd & 3rd trimesters.